Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3240197 | 0.89 | CCR5 (0.39) | AKR1B1CRHBPCRHR2CCR5 | |
| SCHEMBL3246142 | 0.83 | MEN1 (0.36) | ADAM17AKR1B1SYKCRHBPCRHR2 | |
| SCHEMBL3232764 | 0.82 | P2RX7 (0.37) | CRHBPCRHR2 | |
| SCHEMBL3240162 | 0.76 | PTPN1 (0.35) | MAOBCRHBPCRHR2 | |
| SCHEMBL3242646 | 0.74 | RHEB (0.36) | — | |
| SCHEMBL3242221 | 0.74 | CNR1 (0.38) | AKR1B1CCR5 | |
| SCHEMBL3240328 | 0.74 | GPR84 (0.44) | CRHBPCRHR2 | |
| SCHEMBL3240159 | 0.73 | IDO1 (0.38) | CRHBPCRHR2 | |
| SCHEMBL3243672 | 0.70 | P2RX7 (0.38) | AKR1B1PHF8 | |
| SCHEMBL4301010 | 0.68 | MEN1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | claimed |
| WO-2009131947-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | claimed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | disclosed |
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | disclosed |
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-10-29 | — | — | US | disclosed |
| WO-2009131947-A2 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270398-A1 | Compounds, Compositions and Methods Comprising Pyridazine Derivatives | CFTR, PKD1, PKD2 | ADAM17 2117/4885AKR1B1 689/4885SYK 2337/4885 |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | ADAM17 2905/4885AKR1B1 426/4885SYK 3540/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | ADAM17 2905/4885AKR1B1 426/4885SYK 3540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.